POLIVY plus R-CHP reduced the risk of people's cancer worsening or returning by 27% compared with traditional chemoimmunotherapy
POLIVY plus R-CHP was compared with traditional chemoimmunotherapy (R-CHOP) in a large clinical trial of 879 people with newly diagnosed moderate to high risk large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), high-grade B-cell lymphoma (HGBL) and other subtypes of DLBCL. 440 people were randomly assigned to treatment regimen with POLIVY plus R-CHP, and 439 to traditional chemoimmunotherapy.
Another analysis from the study measured the number of people who did not have their disease worsen or return at 2 years with POLIVY or traditional chemoimmunotherapy.*
*There are limitations with these 2-year data. The results are descriptive, which means that researchers looked at what happened in the clinical trial without determining a definitive benefit. Your experience may differ. Talk to your doctor about how to best understand these results.
POLIVY plus R-CHP: the first FDA-approved treatment since 2006 to delay the worsening or returning of cancer in certain types of newly diagnosed DLBCL patients.
Talk with your healthcare team about benefits and risks and whether POLIVY plus R-CHP could be a good treatment option for you.
The information contained in this section of the site is intended for US healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.